EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹2,667 Cr
Expense Ratio
0.61%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+19.17%
+17.55% (Cat Avg.)
3 Years
+18.66%
+18.10% (Cat Avg.)
5 Years
+24.93%
+22.46% (Cat Avg.)
Since Inception
+22.43%
— (Cat Avg.)
Equity | ₹2,655.27 Cr | 99.55% |
Others | ₹12.12 Cr | 0.45% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹317.35 Cr | 11.90% |
Aurobindo Pharma Ltd | Equity | ₹189.86 Cr | 7.12% |
Cipla Ltd | Equity | ₹184.32 Cr | 6.91% |
Divi's Laboratories Ltd | Equity | ₹175.92 Cr | 6.60% |
Lupin Ltd | Equity | ₹165.31 Cr | 6.20% |
Glenmark Pharmaceuticals Ltd | Equity | ₹156.19 Cr | 5.86% |
Apollo Hospitals Enterprise Ltd | Equity | ₹146.25 Cr | 5.48% |
Dr Reddy's Laboratories Ltd | Equity | ₹110.7 Cr | 4.15% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹110.1 Cr | 4.13% |
Suven Pharmaceuticals Ltd | Equity | ₹105.38 Cr | 3.95% |
Mankind Pharma Ltd | Equity | ₹82.78 Cr | 3.10% |
Syngene International Ltd | Equity | ₹80.26 Cr | 3.01% |
Torrent Pharmaceuticals Ltd | Equity | ₹79.22 Cr | 2.97% |
Gland Pharma Ltd | Equity | ₹77.54 Cr | 2.91% |
Wockhardt Ltd | Equity | ₹73.58 Cr | 2.76% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹72.86 Cr | 2.73% |
Sai Life Sciences Ltd | Equity | ₹67.07 Cr | 2.51% |
Alkem Laboratories Ltd | Equity | ₹66.49 Cr | 2.49% |
OneSource Specialty Pharma Ltd | Equity | ₹64.76 Cr | 2.43% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹64.42 Cr | 2.42% |
Fortis Healthcare Ltd | Equity | ₹61.32 Cr | 2.30% |
Ipca Laboratories Ltd | Equity | ₹55.6 Cr | 2.08% |
Biocon Ltd | Equity | ₹32.94 Cr | 1.23% |
Alembic Pharmaceuticals Ltd | Equity | ₹26.91 Cr | 1.01% |
Sagility India Ltd | Equity | ₹22.57 Cr | 0.85% |
Deepak Nitrite Ltd | Equity | ₹18.68 Cr | 0.70% |
Laxmi Dental Ltd | Equity | ₹18.12 Cr | 0.68% |
Neogen Chemicals Ltd | Equity | ₹15.89 Cr | 0.60% |
Treps | Cash - Repurchase Agreement | ₹15.06 Cr | 0.56% |
Zydus Lifesciences Ltd | Equity | ₹12.56 Cr | 0.47% |
Net Receivables / (Payables) | Cash | ₹-3.16 Cr | 0.12% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.32 Cr | 0.01% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.22 Cr | 0.01% |
SRF Ltd | Equity | ₹0.01 Cr | 0.00% |
Large Cap Stocks
32.99%
Mid Cap Stocks
39.58%
Small Cap Stocks
23.87%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,620.7 Cr | 98.25% |
Basic Materials | ₹34.57 Cr | 1.30% |
Industrials | ₹0.01 Cr | 0.00% |
Standard Deviation
This fund
17.14%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.76
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since July 2018
ISIN INF769K01ED6 | Expense Ratio 0.61% | Exit Load 1.00% | Fund Size ₹2,667 Cr | Age 6 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,78,421 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹2,667 Cr
Expense Ratio
0.61%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+19.17%
+17.55% (Cat Avg.)
3 Years
+18.66%
+18.10% (Cat Avg.)
5 Years
+24.93%
+22.46% (Cat Avg.)
Since Inception
+22.43%
— (Cat Avg.)
Equity | ₹2,655.27 Cr | 99.55% |
Others | ₹12.12 Cr | 0.45% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹317.35 Cr | 11.90% |
Aurobindo Pharma Ltd | Equity | ₹189.86 Cr | 7.12% |
Cipla Ltd | Equity | ₹184.32 Cr | 6.91% |
Divi's Laboratories Ltd | Equity | ₹175.92 Cr | 6.60% |
Lupin Ltd | Equity | ₹165.31 Cr | 6.20% |
Glenmark Pharmaceuticals Ltd | Equity | ₹156.19 Cr | 5.86% |
Apollo Hospitals Enterprise Ltd | Equity | ₹146.25 Cr | 5.48% |
Dr Reddy's Laboratories Ltd | Equity | ₹110.7 Cr | 4.15% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹110.1 Cr | 4.13% |
Suven Pharmaceuticals Ltd | Equity | ₹105.38 Cr | 3.95% |
Mankind Pharma Ltd | Equity | ₹82.78 Cr | 3.10% |
Syngene International Ltd | Equity | ₹80.26 Cr | 3.01% |
Torrent Pharmaceuticals Ltd | Equity | ₹79.22 Cr | 2.97% |
Gland Pharma Ltd | Equity | ₹77.54 Cr | 2.91% |
Wockhardt Ltd | Equity | ₹73.58 Cr | 2.76% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹72.86 Cr | 2.73% |
Sai Life Sciences Ltd | Equity | ₹67.07 Cr | 2.51% |
Alkem Laboratories Ltd | Equity | ₹66.49 Cr | 2.49% |
OneSource Specialty Pharma Ltd | Equity | ₹64.76 Cr | 2.43% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹64.42 Cr | 2.42% |
Fortis Healthcare Ltd | Equity | ₹61.32 Cr | 2.30% |
Ipca Laboratories Ltd | Equity | ₹55.6 Cr | 2.08% |
Biocon Ltd | Equity | ₹32.94 Cr | 1.23% |
Alembic Pharmaceuticals Ltd | Equity | ₹26.91 Cr | 1.01% |
Sagility India Ltd | Equity | ₹22.57 Cr | 0.85% |
Deepak Nitrite Ltd | Equity | ₹18.68 Cr | 0.70% |
Laxmi Dental Ltd | Equity | ₹18.12 Cr | 0.68% |
Neogen Chemicals Ltd | Equity | ₹15.89 Cr | 0.60% |
Treps | Cash - Repurchase Agreement | ₹15.06 Cr | 0.56% |
Zydus Lifesciences Ltd | Equity | ₹12.56 Cr | 0.47% |
Net Receivables / (Payables) | Cash | ₹-3.16 Cr | 0.12% |
Eris Lifesciences Ltd Registered Shs | Equity | ₹0.32 Cr | 0.01% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.22 Cr | 0.01% |
SRF Ltd | Equity | ₹0.01 Cr | 0.00% |
Large Cap Stocks
32.99%
Mid Cap Stocks
39.58%
Small Cap Stocks
23.87%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,620.7 Cr | 98.25% |
Basic Materials | ₹34.57 Cr | 1.30% |
Industrials | ₹0.01 Cr | 0.00% |
Standard Deviation
This fund
17.14%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.76
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since July 2018
ISIN INF769K01ED6 | Expense Ratio 0.61% | Exit Load 1.00% | Fund Size ₹2,667 Cr | Age 6 years 10 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹1,78,421 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments